Cardiovascular gene therapy

Lancet

Volumn 355, Issue 9199, 2000, Pages 213-222

  Ylä Herttuala, Seppo ^a   Martin, John F ^b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BASIC FIBROBLAST GROWTH FACTOR; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; FAS LIGAND; HIRUDIN; METALLOPROTEINASE INHIBITOR; NITRIC OXIDE SYNTHASE; REGULATOR PROTEIN; THYMIDINE KINASE; TRANSCRIPTION FACTOR; VASCULOTROPIN;

ANIMAL MODEL; BLOOD FLOW; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLLATERAL CIRCULATION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC DISORDER; HEART MUSCLE ISCHEMIA; HOMEOBOX; HUMAN; LIMB ISCHEMIA; META ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTENOSIS; RETINOBLASTOMA; REVIEW; VEIN GRAFT;

EID: 0034650348     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)04180-X     Document Type: Review

References (153)

1. Morgan R.A., Anderson W.F. Human gene therapy. Annu Rev Biochem. 62:1993;191-217.
2. Nabel E.G., Nabel G.J. Complex models for the study of gene function in cardiovascular biology. Annu Rev Physiol. 56:1994;741-761.
3. Finkel T., Epstein S.E. Gene therapy for vascular disease. FASEB J. 9:1995;843-851.
4. Gibbons G.H., Dzau V.J. Molecular therapies for vascular diseases. Science. 272:1996;689-693.
5. Ylä-Herttuala S. Vascular gene transfer. Curr Opin Lipidol. 8:1997;72-76.
6. Sanghong B., March K.L. Gene therapy for restenosis: getting nearer the heart of the matter. Circ Res. 82:1998;295-305.
7. De Young M.B., Dichek D.A. Gene therapy for restenosis: are we ready? Circ Res. 82:1998;306-313.
8. Stephan D.J., Yang Z.Y., San H.et al. A new cationic liposome DNA complex enhances the efficiency of arterial gene transfer in vivo. Hum Gene Ther. 7:1996;1803-1812.
9. Plank C., Mechtler K., Szoka F.C. Jr., Wagner E. Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. Hum Gene Ther. 7:1996;1437-1446.
10. Turunen M.P., Hiltunen M.O., Ruponen M.et al. Efficient adventitial gene delivery to rabbit carotid artery with cationic polymer-plasmid complexes. Gene Therapy. 6:1999;6-11.
11. Ylä-Herttuala S., Luoma J., Viita H., Hiltunen T., Sisto T., Nikkari T. Transfer of 15-lipoxygenase gene into rabbit iliac arteries results in the appearance of oxidation-specific lipid-protein adducts characteristic of oxidized low density lipoprotein. J Clin Invest. 95:1995;2692-2698.
12. Yee J.-K., Miyanohara A., LaPorte P., Bouic K., Burns J.C., Friedmann T. A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc Natl Acad Sci USA. 91:1994;9564-9568.
13. Newman K.D., Dunn P.F., Owens J.W.et al. Adenovirus-mediated gene transfer into normal arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J Clin Invest. 96:1995;2955-2965.
14. Tripathy S.K., Black H.B., Goldwasser E., Leiden J.M. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med. 2:1996;545-550.
15. Wilson J.M. Adenoviruses as gene-delivery vehicles. N Engl J Med. 334:1996;1185-1187.
16. Svenssn E.C., Marshall D.J., Woodard K.et al. Efficient and stable transduction of cardiomyocytes after intramyocardial injection or intracoronary perfusion with recombinant adeno-associated virus vectors. Circulation. 99:1999;201-205.
17. Bailey S.R. Mechanisms of delivery and local drug technologies. Semin Interv Cardiol. 1:1996;17-23.
18. Laitinen M., Mäkinen K., Manninen H.et al. Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischaemia. Hum Gene Ther. 9:1998;1481-1486.
19. Laitinen M., Zachary I., Breier G.et al. VEGF gene transfer reduces intimal thickening via increased production of nitric oxide in carotid arteries. Hum Gene Ther. 8:1997;1737-1744.
20. Simons M., Edelman E.R., DeKeyser J.L., Langer R., Rosenberg R. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature. 359:1992;67-73.
21. Morishita R., Gibbons G.H., Elison K.E.et al. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J Clin Invest. 93:1994;1458-1464.
22. Laitinen M., Pakkanen T., Luoma J.et al. Gene transfer into the carotid artery using an adventitial collar: comparison of the effectiveness of plasmid-liposome complexes, retroviruses, pseudotyped retroviruses and adenoviruses. Hum Gene Ther. 9:1997;1645-1650.
23. Tsurumi Y., Takeshita S., Chen D.et al. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation. 94:1996;3281-3290.
24. Mack C.A., Patel S.R., Schwarz E.A.et al. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg. 115:1998;168-177.
25. Arras M., Mollnau H., Strasser R.et al. The delivery of angiogenic factors to the heart by microsphere therapy. Nat Biotechnol. 15:1998;159-162.
26. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med. 333:1995;1757-1763.
27. Lawrie A., Brisken A.F., Francis S.E.et al. Ultrasound enhances reporter gene expression after transfection of vascular cells in vitro. Circulation. 99:1999;2617-2620.
28. Villanueva F.S., Jankowski R.J., Klibanov S.et al. Microbubbles targeted to intercellular adhesion molecule-1 bind to activated coronary artery endothelial cells. Circulation. 98:1998;1-5.
29. Lamping K.G., Rios C.D., Chun J.A., Ooboshi H., Davidson B.L., Heistad D.D. Intrapericardial administration of adenovirus for gene transfer. Am J Physiol. 272:1997;310-317.
30. Isner J.M. Angiogenesis and collateral formation. March K.L. Gene transfer in the cardiovascular system: experimental approaches and therapeutic implications. 1997;307-330 Kluwer Academic Publishers, Boston.
31. Ferrara N., Buntling S. Vascular endothelial growth factors, a specific regulator of angiogenesis. Curr Opin Nephrol Hypertens. 5:1996;35-44.
32. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13:1999;9-22.
33. Petrova T.V., Makinen T., Alitalo K. Signaling via vascular endothelial growth factor receptors. Exp Cell Res. 253:1999;117-130.
34. Takeshita S., Zheng L.P., Brogi E.et al. Therapeutic angiogenesis: a single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest. 93:1994;662-670.
35. Banai S., Jaklitsch M.T., Shou M.et al. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation. 89:1994;2183-2189.
36. Lazarous D.F., Shou M., Scheinowitz M.et al. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation. 94:1996;1074-1082.
37. Lindner V., Reidy M.A. Expression of VEGF receptors in arteries after endothelial injury and lack of increased endothelial regrowth in response to VEGF. Arterioscler Thromb Vasc Biol. 16:1996;1399-1405.
38. Shyu K.G., Manor O., Magner M., Yancopoulos G.D., Isner J.M. Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb. Circulation. 98:1998;2081-2087.
39. Takahashi T., Kalka C., Masuda H.et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med. 5:1999;434-438.
40. Pu L-Q., Sniderman A.D., Brassard R.et al. Enhanced revascularization of the ischemic limb by angiogenic therapy. Circulation. 88:1993;208-215.
41. Unger E.F., Banai S., Shou M.et al. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model. Am J Physiol. 266:1994;1588-1595.
42. Giordano F.J., Ping P., McKirnan M.D.et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischaemic region of the heart. Nat Med. 2:1996;534-539.
43. Lopez J.J., Edelman E.R., Stamler A.et al. Angiogenic potential of perivascularly delivered αFGF in a porcine model of chronic myocardial ischemia. Am J Physiol. 274:1998;930-936.
44. Safi J. Jr., Gloe T.R., Riccioni T., Kovesdi I., Capogrossi M.C. Gene therapy with angiogenic factors: a new potential approach to the treatment of ischemic diseases. J Mol Cell Cardiol. 29:1997;2311-2325.
45. van Belle E., Witzenbichler B., Chen D.et al. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor. Circulation. 97:1998;381-390.
46. Ito W.D., Arras M., Winkler B., Scholz D., Schaper J., Schaper W. Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion. Circ Res. 80:1997;829-837.
47. Martins R.N., Chleboun J.O., Sellers P., Sleight M., Muir J. The role of PDGF-BB on the development of the collateral circulation after acute arterial occlusion. Growth Factors. 10:1994;299-306.
48. Stavri G.T., Zachery I.C., Baskerville P.A., Martin J.F., Erusalimsky J.D. Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Circulation. 92:1995;11-14.
49. Waltenberger J. Modulation of growth factor action: implications for the treatment of cardiovascular diseases. Circulation. 96:1997;4083-4094.
50. Lindahl P., Hellström M., Kalén M., Betsholtz C. Endothelial-perivascular cell signaling in vascular development: lessons from knockout mice. Curr Opin Lipidol. 9:1998;407-411.
51. Springer M.L., Chen A.S., Kraft P.E., Bednarski M., Blau H.M. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol Cell. 2:1998;549-558.
52. Moulton K.S., Heller E., Konerding M.A., flynn E., Palinski W., Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation. 99:1999;1726-1732.
53. Fabre J.E., Rivard A., Magner M.et al. Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. Circulation. 99:1999;3043-3049.
54. Kanno S., Oda N., Abe M.et al. Establishment of a simple and practical procedure applicable to therapeutic angiogenesis. Circulation. 99:1999;2682-2687.
55. Narins C.R., Holmes D.R., Topol E.J. A call for provisional stenting: the balloon is back. Circulation. 97:1998;1298-1305.
56. Bittl J.A. Advances in coronary angioplasty. N Engl J Med. 335:1996;1290-1302.
57. Grondin C.M., Campeau L., Lespérance J., Enjalbert M., Bourassa M.G. Comparison of late changes in internal mammary artery and subvenous vein crafts in two consecutive series of patients 10 years after operation. Circulation. 70:1984;208-212.
58. Morishita R., Gibbons G.H., Ellison K.E.et al. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA. 90:1993;8474-8478.
59. Indolfi C., Avvedimento E.V., Rapacciuolo A.et al. Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nat Med. 1:1995;541-545.
60. Morishita R., Gibbons G.H., Horiuchi M.et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA. 92:1995;5855-5859.
61. Pollman M.J., Hall J.L., Mann M.J., Zhang L., Gibbons G.H. Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease. Nat Med. 2:1998;222-227.
62. Morishita R., Sugimoto T., Aoki M.et al. In vivo transfection of cis element "decoy" against nuclear factor-κB binding site prevents myocardial infarction. Nat Med. 3:1997;894-899.
63. Iaccarino G., Smithwick L.A., Lefkowitz R.J., Koch W.J. Targeting Gbeta gamma signaling in arterial vascular smooth muscle proliferation: a novel strategy to limit restenosis. Proc Natl Acad Sci USA. 96:1999;3945-3950.
64. Burgess T.L., Fisher E.F., Ross S.L.et al. The antiproliferative activity of c-myb and c-myc antisense oligonicleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc Natl Acad Sci USA. 92:1995;4051-4055.
65. Chang M.W., Barr E., Lu M.M., Barton K., Leiden J.M. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest. 96:1995;2260-2268.
66. Yang Z.Y., Simari R.D., Perkins N.D., San H., Gordon D., Nabel G.J. Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury. Proc Natl Acad Sci USA. 93:1996;9705-9710.
67. Tanner F.C., Yang Z.Y., Duckers E., Gordon D., Nabel G.J., Nabel E.G. Expression of cyclin-dependent kinase inhibitors in vascular disease. Circ Res. 82:1998;396-403.
68. Smith R., Branellec D., Gorski D.et al. P21CIP1-mediated inhibition of cell proliferation by overexpression of the gax homeodomain gene. Genes Dev. 11:1997;1674-1689.
69. Yonemitsu Y., Kaneda Y., Tanaka S.et al. Transfer of wild-type p53 gene effectively inhibits vascular smooth muscle cell proliferation in vitro and in vivo. Circ Res. 82:1998;147-156.
70. Ohno T., Gordon S., San H.et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science. 265:1994;781-784.
71. Guzman R.J., Hirschowitz E.A., Brody S.L., Crystal R.G., Epstein S.E., Finkel T. In vivo suppression of injury-mediated transfer of the herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci USA. 91:1994;10732-10736.
72. Chang M.W., Barr E., Seltzer K.et al. Cyctostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science. 267:1995;518-522.
73. Harrell R.L., Rajanayagam S., Doanes A.M.et al. Inhibition of vascular smooth muscle cell proliferation and neointimal accumulation by adenovirus-mediated gene transfer of cytosine deaminase. Circulation. 96:1997;621-627.
74. Sata M., Perlman H., Muruve D.A.et al. Fas ligand gene transfer to the vessel wall inhibits meointima formation and overrides the adenovirus-mediated T cell response. Proc Natl Acad Sci USA. 95:1998;1213-1217.
75. Bai H., Morishita R., Kida I.et al. Inhibition of intimal hyperplasia after vein grafting by in vivo transfer of human senescent cell-derived inhibitor-1 gene. Gene Ther. 5:1998;761-769.
76. Nikol S., Huehns T.Y., Krausz E.et al. Needle injection catheter delivery of the gene for an antibacterial agent inhibits neointimal formation. Gene Ther. 6:1999;737-748.
77. Ferns G.A.A., Raines E.W., Sprugel K.H., Motani A.S., Reidy M.A., Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science. 253:1991;1129-1132.
78. Hart C.E., Kraiss L.W., Vergel S.et al. PDGFβ receptor blockade inhibits intimal hyperplasia in the baboon. Circulation. 99:1999;564-569.
79. Chen S.-J., Wilson J.M., Muller D.W.M. Adenovirus-mediated gene transfer of soluble vascular cell adhesion molecule to porcine interposition vein grafts. Circulation. 89:1994;1922-1928.
80. von der Leyen H.E., Gibbons G.H., Morishita R.et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA. 92:1995;1137-1141.
81. Janssens S., Flaherty D., Nong Z.et al. Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats. Circulation. 97:1998;1274-1281.
82. Kullo I.J., Mozes G., Schwartz R.S.et al. Adventitial gene transfer of recombinant endothelial nitric oxide synthase to rabbit carotid arteries alters vascular reactivity. Circulation. 96:1997;2254-2261.
83. George S.J., Johnson J.L., Angelini G.D., Newby A.C., Baker A.H. Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. Hum Gene Ther. 9:1998;867-877.
84. Cheng L., Mantile G., Pauly R.et al. Adenovirus-mediated gene transfer of the human tissue inhibitor of metalloproteinase-2 blocks vascular smooth muscle cell invasiveness in vitro and modulates neointimal development in vivo. Circulation. 98:1998;2195-2201.
85. Numaguchi Y., Naruse K., Harada M.et al. Prostacyclin synthase gene transfer accelerates reendothelialisation and inhibits neointimal formation in rat carotid arteries after balloon injury. Arterioscler Thromb Vasc Biol. 19:1999;727-733.
86. Van der Zee R., Murohara T., Luo S.et al. Vascular endothelial growth factor/vascular permeability factors augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation. 95:1997;1030-1037.
87. Wheeler-Jones C., Abu-Ghazaleh R., Cospedal R., Houliston R.A., Martin J., Zachary I. Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase. FEBS Lett. 420:1997;28-32.
88. Laitinen M., Hartikainen J., Eränen J.et al. Catheter-mediated VEGF gene transfer to human coronary arteries after angioplasty. Hum Gene Ther. 110:2000;263-270.
89. Van Belle E., Tio F.O., Chen D.et al. Passivation of metallic stents after arterial gene transfer of phVEGF165 inhibits thrombus formation and intimal thickening. J Am Coll Cardiol. 29:1997;1371-1379.
90. Ylä-Herttuala S., Nikkari T., Hirvonen J.et al. Biochemical composition of coronary arteries in Finnish children. Arteriosclerosis. 6:1986;230-236.
91. Grossman M., Rader D.J., Muller D.M.W.et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med. 1:1995;1148-1154.
92. Kozarsky K.F., McKinley D.R., Austin L.L., Raper S.E., Stratford-Perricaudet L.D., Wilson J.M. In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidaemic rabbit with recombinant adenoviruses. J Biol Chem. 29:1994;13695-13703.
93. Pakkanen T., Laitinen M., Hippeläinen M.et al. Enhanced plasma cholesterol lowering effect of retrovirus-mediated LDL receptor gene transfer to WHHL rabbit liver after improved surgical technique and stimulation of hepatocyte poliferation by combined partial liver resection and thymidine kinase-ganciclovir treatment. Gene Ther. 6:1999;34-41.
94. Kozarsky K.F., Jooss K., Donahee M.et al. Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene. Nat Genet. 13:1996;54-62.
95. Zsigmont E., Kobayashi K., Tzung K.W., Li I., Fuke Y., Chan L. Adenovirus-mediated gene transfer of human lipoprotein lipase ameliorates the hyperlipidemias associated with apolipoprotein E and LDL receptor deficiencies in mice. Hum Gene Ther. 8:1997;1921-1933.
96. Ashbourne Excoffon K.J., Liu G., Miao L.et al. Correction of hypertriglyceridemia and impaired fat tolerance in lipoprotein lipase-deficient mice by adenovirus-mediated expression of human lipoprotein lipase. Arterioscler Thromb Vasc Biol. 17:1997;2532-2539.
97. Applebaum-Bowden D., Kobayashi J., Kashyap V.S.et al. Hepatic lipase gene therapy in hepatic lipase-deficient mice. Adenovirus-mediated replacement of a lipolytic enzyme to the vascular endothelium. J Clin Invest. 97:1996;799-805.
98. Dugi K.A., Vaisman B.L., Sakai N.et al. Adenovirus-mediated expression of hepatic lipase in LCAT transgenic mice. J Lipid Res. 38:1997;1822-1832.
99. Greeve J., Jona V.K., Chowdhury N.R.et al. Hepatic gene transfer of the catalytic subunit of the apolipoprotein B mRNA editing enzyme results in a reduction of plasma ldl levels in normal and watanabe heritable hyperlipidemic rabbits. J Lipid Res. 37:1996;2001-2017.
100. Kozarsky K.F., Bonen D.K., Giannoni F.et al. Hepatic expression of the catalytic subunit of the apolipoprotein B mRNA editing enzyme (apobec-1) ameliorates hypercholesterolemia in LDL receptor-deficient rabbits. Hum Gene Ther. 7:1996;943-957.
101. Brousseau M.E., Wang J., Demosky S.J.J.et al. Correction of hypoalphalipoproteinemia in LDL receptor-deficient rabbits by lecithin:cholesterol acyltransferase. J Lipid Res. 39:1998;1558-1567.
102. Seguret-Mace S., Latta-Mahieu M., Castro G.et al. Potential gene therapy for lecithin-cholesterol acyltransferase (LCAT)-deficient and hypoalphalipoproteinemic patients with adenovirus-mediated transfer of human LCAT gene. Circulation. 94:1996;2177-2184.
103. Fan L., Drew J., Dunckley M.G.et al. Efficient coexpression and secretion of anti-atherogenic human apolipoprotein AI and lecithin-cholesterol acyltransferase by cultured muscle cells using adeno-associated virus plasmid vectors. Gene Ther. 5:1998;1434-1440.
104. Ehnholm S., van Dijk K.W., van't Hof.et al. Adenovirus mediated overexpression of human phospholipid transfer protein alters plasma HDL levels in mice. J Lipid Res. 39:1998;1248-1253.
105. Morishita R., Yamada S., Yamamoto K.et al. Novel therapeutic strategy for atherosclerosis: ribozyme oligonucleotides against apolipoprotein(a) selectively inhibit apolipoprotein (a) but not plasminogen expression. Circulation. 98:1998;1898-1904.
106. Kopfler W.P., Willard M., Betz T.et al. Adenovirus-mediated transfer of a gene encoding human apolipoprotein A-I into normal mice increases circulating high-density lipoprotein cholesterol. Circulation. 90:1994;1319-1327.
107. De Geest B., Zhao Z., Collen D., Holvoet P. Effects of adenovirus-mediated human apo A-I gene transfer on neointima formation after endothelial denudation in apo E-deficient mice. Circulation. 96:1997;4349-4356.
108. Tsukamoto K., Hiester K.G., Smith P.et al. Comparison of human apoA-I expression in mouse models of atherosclerosis after gene transfer using a second generation adenovirus. J Lipid Res. 38:1997;1869-1876.
109. Benoit P., Emmanuel F., Caillaud J.M.et al. Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models. Circulation. 99:1999;105-110.
110. Shah P.K., Nilsson J., Kaul S.et al. Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation. 97:1998;780-785.
111. Kashyap V.S., Santamarina-Fojo S., Brown D.R.et al. Apolipoprotein E deficiency in mice: gene replacement and prevention of atherosclerosis using adenovirus vectors. J Clin Invest. 96:1995;1612-1620.
112. Tsukamoto K., Smith P., Glick J.M., Rader D.J. Liver-directed gene transfer and prolonged expression of three major human ApoE isoforms in ApoE-deficient mice. J Clin Invest. 100:1997;107-114.
113. Bellosta S., Mahley R., Sanan D.et al. Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic E-null mice. J Clin Invest. 96:1995;2170-2179.
114. Hasty A.H., Linton M.R.F., Brandt S.J., Babaev V.R., Gleaves L.A., Fazio S. Retroviral gene therapy in apoE-deficient mice. ApoE expression in the artery wall reduces early foam cell lesion formation. Circulation. 99:1999;2571-2576.
115. Ylä-Herttuala S., Palinski W., Rosenfeld M.E.et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 84:1989;1086-1095.
116. Kodama T., Freeman M., Rohrer L.et al. Type I macrophage scavenger receptor contains alpha-helical and collagen-like coiled coils. Nature. 343:1990;531-535.
117. Laukkanen J., Lehtolainen P., Gough P., Greaves D., Gordon S., Ylä-Herttuala S. Secreted macrophage scavenger receptor competes for modified low density lipoprotein degradation and prevents foam cell formation in marophages. Circulation. 98:1998;I-108. (abstr).
118. Kozarsky K.F., Donahee M.H., Rigotti A.et al. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature. 387:1997;414-417.
119. Miwa K., Igawa A., Inoue H. Soluble E-selectin, ICAM-1 and VCAM-1 levels in systemic and coronary circulation in patients with variant angina. Cardiovasc Res. 36:1997;37-44.
120. Phillips M.I. Is gene therapy for hypertension possible? Hypertension. 33:1999;8-13.
121. Leor J., Prentice H., Sartorelli V.et al. Gene transfer and cell transplant: an experimental approach to repair a 'broken heart'. Cardiovasc Res. 35:1997;431-441.
122. Shi C., Russell M.E., Bianchi C., Newell J.B., Haber E. Murine model of accelerated transplant arteriosclerosis. Circ Res. 75:1994;199-207.
123. Allaire E., Forough R., Clowes M., Starcher B., Clowes A.W. Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model. J Clin Invest. 102:1998;1413-1420.
124. Rade J.J., Schulick A.H., Virmani R., Dichek D.A. Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury. Nat Med. 2:1996;293-298.
125. Waugh J.M., Kattash M., Li J.et al. Gene therapy to promote thromboresistance: local overexpression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model. Proc Natl Acad Sci USA. 96:1999;1065-1070.
126. Zoldhelyi P., McNatt J., Xu X.M.et al. Prevention of arterial thrombosis by adenovirus-mediated transfer of cyclooxygenase gene. Circulation. 93:1996;10-17.
127. Waugh J.M., Yuksel E., Li J.et al. Local overexpression of thrombomodulin for in vivo prevention of arterial thrombosis in a rabbit model. Circ Res. 84:1999;84-92.
128. Nishida T., Ueno H., Atsushi N.et al. Adenovirus-mediated local expression of human tissue factor pathway inhibitor eliminates shear stress-induced recurrent thrombosis in the injured carotid artery of the rabbit. Circ Res. 84:1999;1446-1452.
129. Dunn P.F., Newman K.D., Jones M.et al. Seeding of vascular grafts with genetically modified endothelial cells. Secretion of recombinant TPA results in decreased seeded cell retention in vitro and in vivo. Circulation. 93:1996;1439-1446.
130. 165 in patient with ischaemic limb. Lancet. 348:1996;370-374.
131. 165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation. 97:1998;1114-1123.
132. Isner J.M., Baumgartner I., Rauh G.et al. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J Vasc Surg. 28:1998;964-973.
133. Losordo D.W., Vale P.R., Symes J.F.et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF (165) as sole therapy for myocardial ischaemia. Circulation. 98:1998;2800-2804.
134. Mäkinen K., Laitinen M., Manninen H., Matsi P., Alhava E., Yliä-Herttuala S. Catheter-mediated VEGF gene transfer to human lower limb arteries after PTA. Circulation. 100:1999;I-770.
135. Mann M.J., Whittemore A.D., Donaldson M.C.et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet. 354:1999;1493-1498.
136. Rosengart T.K., Lee L.Y., Patel S.R.et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation. 100:1999;468-474.
137. Sellke F.W., Laham R.J., Edelman E.R., Pealman J.D., Simons M. Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Ann Thorac Surg. 65:1998;1540-1544.
138. Laham R.J., Selke F.W., Edelman E.R.et al. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. Circulation. 100:1999;1865-1871.
139. Laham R.J., Leimbach M., Chronos N.S.et al. Intracoronary administration of recombinant fibroblast growth factor (rFGF-2) in patients with severe coronary artery disease: results of phase I. J Am Coll Cardiol. 33:1999;383.
140. Schumacher B., Pecher P., von Specht B.U., Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation. 97:1998;645-650.
141. Henry T.D., Annex B.H., Azrin M.A.et al. Double blind, placebo controlled trial of recombinant human vascular endothelial growth factor: the VIVA Trial. J Am Coll Cardiol. 33:1999;384.
142. Lehrman S. Virus treatment questioned after gene therapy death. Nature. 401:1999;517-518.
143. Zanta M.A., Belguise-Valladier P., Behr J-P. Gene delivery: a single nuclear localization signal peptide is sufficient to carry DNA to the cell nucleus. Proc Natl Acad Sci USA. 96:1999;91-96.
144. Bilbao G., Contreras J.L., Gomez-Navarro J., Curiel D.T. Improving adenoviral vectors for cancer therapy. Tumor Target. 3:1998;59-79.
145. Cole-Strauss A., Yoon K., Xiang Y.et al. Correction of the mutation responsible for sickle cell anemia by an RNA-DNA oligonucleotide. Science. 273:1996;1386-1389.
146. Lan N., Howry R.P., Lee S-W., Smith C.A., Sullenger B.A. Ribozyme-mediated repair of sickle β-globin mRNAs in erythrocyte precursors. Science. 280:1998;1593-1596.
147. Manninen H.I., Vanninen R.L., Laitinen M.et al. 1998 Intravascular ultrasound and magnetic resonance imaging in the assessment of atherosclerotic lesions in rabbit aorta; correlation to histopathological findings. Invest Radiol. 33:1998;464-471.
148. 1MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma: implications for the in vivo detection of apoptosis. Nat Med. 5:1999;1323-1327.
149. Arap W., Pasqualini R., Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 279:1998;377-380.
150. Burcin M.M., Schiedner G., Kochanek S., Tsai S.Y., O'Malley B.W. Adenovirus-mediated regulable target gene expression in vivo. Proc Natl Acad Sci USA. 96:1999;355-360.
151. Ye X., Rivera V.M., Zoltick P.et al. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science. 283:1999;88-91.
152. Symes J.F., Losardo D.W., Vale P.R.et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg. 68:1999;830-837.
153. Lazarous D.F., Unger E.F., Epstein S.E.et al. Effect of basic fibroblast growth factor on lower extremity blood flow in patients with intermittent claudication: preliminary results. Circulation. 98:1998;I-456.